Incyte Stock Performance Outpaces Market Amid Strong Earnings and Analyst Upgrades
Incyte Corporation (INCY) has outperformed both the S&P 500 Index ($SPX) and the health care sector ETF XLV over the past year, with its stock rising by 42.1% compared to SPX's gain of 20.1%. The biopharmaceutical company reported strong Q2 results in July 2026, including a 40% increase in net sales and an adjusted EPS of $3.09 that exceeded analyst expectations. The stock received a boost after Incyte raised its full-year revenue forecast to between $5.13 billion and $5.26 billion following a CMS settlement expected to add up to $310 million in Opzelura sales. Analysts remain cautiously optimistic, with 26 covering the stock offering a
